Relmada Therapeutics announced it will present updated 12-month Phase 2 data for NDV-01, a sustained-release bladder cancer treatment, at the American Urology Association meeting in May 2026. The data show a 95% complete response rate at any time and a durable 76% response at 12 months in high-risk non-muscle invasive bladder cancer (NMIBC). Relmada also plans to share an overview of its Phase 3 RESCUE trial, which is on track to start mid-2026. This progress highlights NDV-01's potential as a convenient, effective therapy for a bladder cancer subtype with limited options.
During week 21 of 2026 (May 18-22), Sampo Oyj bought back a total of 1,911,568 of its own A-shares across multiple exchanges at a weighted average price of €9.21 per share. This buyback is part of a program authorized by the company's annual general ...
The PGIM Global High Yield Fund (GHY) provides investors with diversified exposure to below-investment-grade fixed income globally, including a 45% allocation to U.S. assets and over 900 holdings. It currently trades at a 7.3% discount, which is attr...
Schaeffler's stock rating is maintained at 'Hold' with a reduced price target of €4 per share due to ongoing structural and execution challenges. The company's e-mobility division continues to report significant negative EBIT margins, which offset pr...
Singapore reported April headline inflation at 1.8%, below the expected 2%, and core inflation at 1.4%, also under forecasts. The Monetary Authority of Singapore warned that imported cost pressures could rise due to energy and supply chain issues lin...
Gold and silver prices increased due to a weaker U.S. dollar and lower U.S. Treasury yields, driven by a drop in oil prices following eased tensions in the Strait of Hormuz. Spot gold rose over 1% to $4,560 and silver reached $78 per ounce. The decli...
